Dealing with cancer screening in the COVID-19 era

Fagundes, Thales Pardini; Albuquerque, Ronniel Morais; Miranda, Diego Lopes Paim; Landeiro, Luciana Castro Garcia; Ayres, Gabriel Souza Fontes; Correia, Caenna Corrêa E; Nogueira-Rodrigues, Angélica

doi:10.1590/1806-9282.67.suppl1.20200889

Cited by 15 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This raises the rather alarming question of what happened to all those missing cases: were they diagnosed in good time through alternative pathways or do they still remain undiagnosed? Therefore, a long-term consequence of the pandemic may well be that these missed diagnoses will be picked up later, indirectly adding to the morbidity and mortality from SARS-CoV-2 [ 12 ].…”

Section: Impact On the Initial Presentation Of Patients With Potential Cancermentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali

Riches

2021

Cancers

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has caused considerable global disruption to clinical practice. This article will review the impact that the pandemic has had on oncology clinical trials. It will assess the effect of the COVID-19 situation on the initial presentation and investigation of patients with suspected cancer. It will also review the impact of the pandemic on the subsequent management of cancer patients, and how clinical trial approval, recruitment, and conduct were affected during the pandemic. An intriguing aspect of the pandemic is that clinical trials investigating treatments for COVID-19 and vaccinations against the causative virus, SARS-CoV-2, have been approved and conducted at an unprecedented speed. In light of this, this review will also discuss the potential that this enhanced regulatory environment could have on the running of oncology clinical trials in the future.

show abstract

Section: Impact On the Initial Presentation Of Patients With Potential Cancermentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

Ali

Riches

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…A pandemia da covid-19 impactou globalmente a realização de exames e procedimentos cirúrgicos 4 . O tratamento do câncer de mama, que envolve a cooperação multidisciplinar de diversos profissionais de saúde, foi uma das áreas que sofreram com atrasos e cancelamentos significativos 15 .…”

Section: Discussionunclassified

“…Segundo a OMS noticiou no início da pandemia, 90% dos países relataram uma ou mais interrupções nos serviços essenciais de saúde 3 . A prioridade, desse modo, passou a ser os serviços de urgência e emergência, gerando repercussões nas consultas ambulatoriais e nos exames de rotina, o que acabou atrasando o diagnóstico de doenças, como os cânceres de mama, colo do útero, próstata e colorretal 4 .…”

Section: Introductionunclassified

O Impacto da Pandemia da Covid-19 no Volume de Mamografias no Brasil: uma Análise de Previsão Baseada nos Números Históricos

Demarchi

Maurer

Pierini

et al. 2022

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: A neoplasia mamaria constitui a primeira causa de óbito por câncer em mulheres brasileiras. Dados sobre o real impacto da pandemia na política de rastreamento e diagnostico do câncer de mama no Brasil ainda são desconhecidos. Objetivo: Avaliar o efeito da pandemia da covid-19 no número de mamografias realizadas no Sistema Único de Saúde (SUS). Método: Estudo epidemiológico, quantitativo e de delineamento transversal. Foram selecionadas mamografias mensais realizadas no SUS após consulta ao Departamento de Informática do SUS (DATASUS). Foi avaliado o volume histórico, de janeiro de 2017 a marco de 2020, mês seguinte ao primeiro caso de covid-19 diagnosticado no Brasil, para se construir um modelo de previsão das mamografias esperadas de marco de 2020 até dezembro de 2021. Resultado: No ano de 2020, 1.705.475 mamografias deixaram de ser realizadas no Brasil em relação ao ano anterior, segundo o DATASUS. O modelo de previsão, com base nos valores históricos, mostrou um déficit de 1.635.42 mamografias. Em maio de 2020, ocorreu a maior queda na realização dos exames, representando apenas 20,69% das mamografias realizadas no mesmo mês do ano anterior. Conclusão: A detecção precoce do câncer de mama foi uma das áreas medicas impactadas pela política de restrição e isolamento impostos no ano de 2020. Nesse sentido, esforços governamentais futuros serão necessários para oferecer tratamento a eventuais pacientes com diagnostico tardio de câncer de mama, além das mamografias que não puderam ser realizadas.

show abstract

“…Risk stratification and triage was recommended as an appropriate method for focusing cancer screenings during the COVID-19 pandemic. The recommendation focused on prioritizing those who are most susceptible to developing cancers [6,9,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]. Potential criteria considered for categorizing patients into high risk included patients with an abnormal or suspicious result on the previous screening test [27], age group [17,26,32], sex [26], personal medical or family history [18,24,26,27], currently symptomatic or asymptomatic, predisposition to hereditary cancers, and inheritance of cancer-causing mutations [18,26].…”

Section: Risk Stratification and Triagementioning

confidence: 99%

“…Conversely, articles recommended the following patients be deferred until high priority patients are offered cancer screenings: patients with a recent cancer screening with normal results [17,20]; patients who do not have any cancer-related symptoms [18,22]; patients who have taken prophylactic measures such as the human papillomavirus (HPV) prophylactic vaccine [17,20,24]; and patients who do not have medical, personal, or family-related indication for immediate screening [18,19,23,31].…”

Section: Risk Stratification and Triagementioning

confidence: 99%

Cancer Screening Recommendations During the COVID-19 Pandemic: Scoping Review

Shah¹,

McElfish²

2022

JMIR Cancer

View full text Add to dashboard Cite

Background Cancer screening tests are recommended to prevent cancer-associated mortality by detecting precancerous and cancerous lesions in early stages. The COVID-19 pandemic disrupted the use of preventive health care services. Although there was an increase in the number of cancer screening tests beginning in late 2020, screenings remained 29% to 36% lower than in the prepandemic era. Objective The aim of this review is to assist health care providers in identifying approaches for prioritizing patients and increasing breast, cervical, and colorectal cancer screening during the uncertainty of the COVID-19 pandemic. Methods We used the scoping review framework to identify articles on PubMed and EBSCO databases. A total of 403 articles were identified, and 23 articles were selected for this review. The literature review ranged from January 1, 2020, to September 30, 2021. Results The articles included two primary categories of recommendations: (1) risk stratification and triage to prioritize screenings and (2) alternative methods to conduct cancer screenings. Risk stratification and triage recommendations focused on prioritizing high-risk patients with an abnormal or suspicious result on the previous screening test, patients in certain age groups and sex, patients with a personal medical or family cancer history, patients that are currently symptomatic, and patients that are predisposed to hereditary cancers and cancer-causing mutations. Other recommended strategies included identifying areas facing the most disparities, creating algorithms and using artificial intelligence to create cancer risk scores, leveraging in-person visits to assess cancer risk, and providing the option of open access screenings where patients can schedule screenings and can be assigned a priority category by health care staff. Some recommended using telemedicine to categorize patients and determine screening eligibility for patients with new complaints. Several articles noted the importance of implementing preventive measures such as COVID-19 screening prior to the procedures, maintaining hygiene measures, and social distancing in waiting rooms. Alternative screening methods that do not require an in-person clinic visit and can effectively screen patients for cancers included mailing self-collection sampling kits for cervical and colorectal cancers, and implementing or expanding mobile screening units. Conclusions Although the COVID-19 pandemic had devastating effects on population health globally, it could be an opportunity to adapt and evolve cancer screening methods. Disruption often creates innovation, and focus on alternative methods for cancer screenings may help reach rural and underresourced areas after the pandemic has ended.

show abstract

Dealing with cancer screening in the COVID-19 era

Cited by 15 publications

References 21 publications

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

O Impacto da Pandemia da Covid-19 no Volume de Mamografias no Brasil: uma Análise de Previsão Baseada nos Números Históricos

Cancer Screening Recommendations During the COVID-19 Pandemic: Scoping Review

Contact Info

Product

Resources

About